MMs are a POS!......That´s all I can say. Most don´t know where the markets are heading and some are nothing but crooks. CYTK should be valued at least 2 bucks, fair value, but this guys are the drivers and there´s nothing small fishes can do but wait. F.U.C.K. them all!
<AMGN reports on Thursday. Hopefully, we may learn something about the joint CV program during the conference call or quarterly release.>
I check the AMGN website daily to see if there are any changes in phase 2 comments for AMG 423:
Omecamtiv mecarbil is a small molecule activator of cardiac myosin. Omecamtiv mecarbil is being investigated to improve cardiac contractility in subjects with heart failure. We are developing this product in collaboration with Cytokinetics, Inc. ("Cytokinetics").